{"id":"W4281673802","doi":"10.1200/jco.2022.40.16_suppl.tps5096","title":"TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Olaparib; PARP inhibitor; Prostate cancer; Placebo; Internal medicine; Androgen receptor; Oncology; Cancer; Pathology; Poly ADP ribose polymerase; Genetics; Biology; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020675,0.002477581,0.003004193,0.0005940455,0.000600335,0.001498632,0.00146444,0.002419819,0.009255128],"category_scores_gemma":[0.001696334,0.0009213981,0.002265088,0.0005006321,0.001397198,0.00172404,0.0004851584,0.004677323,0.001761154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009922156,"about_ca_system_score_gemma":0.001791109,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001367611,"about_ca_topic_score_gemma":0.003924584,"domain_scores_codex":[0.9994426,0.0002693869,0.00002862831,0.0001087756,0.00004463427,0.000105923],"domain_scores_gemma":[0.999011,0.0002256848,0.0001973952,0.00006508354,0.00007325598,0.000427422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970583,0.013437,0.0002858224,0.0004655908,0.0007846343,0.00004337627,0.00004931869,0.0003965457,0.003567744,0.0001384636,0.001140801,0.009107823],"study_design_scores_gemma":[0.9396827,0.05823326,0.0006011193,0.00001509775,0.0002444992,0.00002541724,0.00001706926,0.00036836,0.0002550787,0.0001356039,0.0004059934,0.00001568288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9712954,0.00527941,0.001526227,0.001775373,0.001267866,0.01108481,0.003261571,0.0005010489,0.004008385],"genre_scores_gemma":[0.9660122,0.003594708,0.003524062,0.003859329,0.00074977,0.01197701,0.003050158,0.00009391904,0.00713869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009255128,"threshold_uncertainty_score":0.03096151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1576914169105703,"score_gpt":0.4849085811949972,"score_spread":0.3272171642844269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}